The USFDA has approved Sernivo Spray (Betamethasone dipropionate), a topical corticosteroid for treatment of mild to moderate plaque psoriasis. The drug is to be manufactured by Promius Pharma LLC.
Two double-blinded, randomized, controlled studies were conducted to demonstrate the safety and efficacy of Sernivo Spray. The subjects were randomized to receive Sernivo Spray or a placebo spray, twice daily for 28 days. At 29th day, about 42.7% and 34.5% of patients have achieved treatment success, compared to 11.7% and 13.6% in placebo group.
Some of the reported common adverse events were atrophy at the application site, pruritus, pain and burning or stinging sensation.